Back to search

Peptide record

TPDB13323

Antibacterial Hemolysis Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13323
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
WFGKLYRGITKVVKKVKGLLKG
Physicochemical Analysis
C122H204N32O25
ANDCEQHMPS
K
2519.16
11.22
7
0
10
+7
1.23
-0.050
110.45
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
6990
277.47
2
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
1
I
3
L
6
K
0
M
1
F
0
P
0
S
1
T
1
W
1
Y
3
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 3 K: 6 M: 0 F: 1 P: 0 S: 0 T: 1 W: 1 Y: 1 V: 3
Chemical Descriptors
22
C122H204N32O25
2519.16
11.22
+7
1.23
-0.050
Evidence Records 12 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.3-1.2 µM

Target

Klebsiella pneumoniae KPC

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.3-1.2 uM), ESBL E. coli (MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC
Evidence 2 Activity

Activity

MIC
Antibacterial
0.6-2.5 µM

Target

Escherichia coli

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.3-1.2 uM), ESBL E. coli (MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (M
Evidence 3 Activity

Activity

MIC
Antibacterial
0.6-1.2 µM

Target

A. baumannii

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 0.3-1.2 uM), ESBL E. coli (MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MI
Evidence 4 Activity

Activity

MIC
Antibacterial
1.2-5.0 µM

Target

Pseudomonas aeruginosa

Source & Reference

NA

Other

C (MIC 0.3-1.2 uM), ESBL E. coli (MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MIC 0.6-2.5 uM), and E. faecalis anti-
Evidence 5 Activity

Activity

MIC
Antibacterial
5.0-19.9 µM

Target

Staphylococcus aureus MRSA

Source & Reference

NA

Other

(MIC 0.6-2.5 uM), XDR A. baumannii (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MIC 0.6-2.5 uM), and E. faecalis anti-VRE (MIC 0.6-2.5 uM). In total, 70
Evidence 6 Activity

Activity

MIC
Antibacterial
0.6-2.5 µM

Target

Staphylococcus epidermidis

Source & Reference

NA

Other

i (MIC 0.6-1.2 uM), MDR P. aeruginosa (MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MIC 0.6-2.5 uM), and E. faecalis anti-VRE (MIC 0.6-2.5 uM). In total, 70 clinical strains were tested and
Evidence 7 Activity

Activity

MIC
Antibacterial
0.6-2.5 µM

Target

Enterococcus faecalis anti-VRE

Source & Reference

NA

Other

(MIC 1.2-5.0 uM), S. aureus MRSA (MIC 5.0-19.9 uM), S. epidermidis (MIC 0.6-2.5 uM), and E. faecalis anti-VRE (MIC 0.6-2.5 uM). In total, 70 clinical strains were tested and the results are expressed as a range. Also
Evidence 8 Activity

Activity

10% Hemolysis
Toxicity
13 µM
Hemolytic Cytotoxic
10% Hemolysis | 13 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 9 Activity

Activity

24% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
24% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 10 Activity

Activity

40% Killing
Toxicity
6.3 µM
Cytotoxic
40% Killing | 6.3 | µM | target cell: Human fibroblasts FB789

Target

Human fibroblasts FB789

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 11 Activity

Activity

100% Killing
Toxicity
25 µM
Cytotoxic
100% Killing | 25 | µM | target cell: Human fibroblasts FB789

Target

Human fibroblasts FB789

Source & Reference

NA
DBAASP
Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens | RSC Adv | 2018
Evidence 12 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis